ARS Pharmaceuticals, Inc. SPRY Accounts Payable
Accounts Payable at other companies
Other financials
Where this comes from
Reported directly by ARS Pharmaceuticals, Inc. in its filing.
Tagged under the XBRL concept us-gaap:AccountsPayableAndAccruedLiabilitiesCurrent.
The official record: ARS Pharmaceuticals, Inc.’s 10-Q, filed May 15, 2026, on SEC EDGAR. View the filing →
Ask your AI about ARS Pharmaceuticals, Inc.'s accounts payable.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude
Questions, answered.
- What is ARS Pharmaceuticals, Inc.'s accounts payable?
- ARS Pharmaceuticals, Inc. (SPRY) reported accounts payable of $48.26M in Q1 2026.
- How has ARS Pharmaceuticals, Inc.'s accounts payable changed year-over-year?
- ARS Pharmaceuticals, Inc.'s accounts payable increased by 78.7% year-over-year, from $27.01M to $48.26M.
- What is the long-term trend for ARS Pharmaceuticals, Inc.'s accounts payable?
- Over 5 years (2020 to 2025), ARS Pharmaceuticals, Inc.'s accounts payable has grown at a 71.2% compound annual growth rate (CAGR), from $2.58M to $37.95M.
- What does accounts payable mean?
- Amounts owed to suppliers and vendors for goods and services received but not yet paid. A primary source of short-term trade financing.